Clinical Trial Update: Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating allogeneic natural killer (NK) cell therapy in patients with malignant lymphomas or solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• Allogeneic NK cell therapy (ex vivo-cultured allogeneic natural killer (NK) cells)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Malignant Lymphomas, Solid Tumors | Phase 1 | Status: COMPLETED